The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gene therapy for lipoprotein lipase deficiency
Abstract
PURPOSE OF REVIEW: The present review summarizes the clinical development of adeno-associated viral vector (AAV)1-lipoprotein lipase (LPL)S447X gene therapy (alipogene tiparvovec) for lipoprotein lipase deficiency. Lipoprotein lipase deficiency is a rare inherited disease characterized by severe hypertriglyceridaemia, chylomicronaemia and risk of recurrent pancreatitis or other complications. AAV1-LPLS447X gene therapy is based on the rationale that by adding episomal copies of functional LPL genes into muscle cells lacking active LPL, metabolic function could be improved or restored. RECENT FINDINGS: AAV1-LPLS447X is a nonreplicating and nonintegrating AAV of serotype 1 designed to deliver and express the human LPL gene variant S447X. The clinical development programme for AAV1-LPLS447X consisted of two observational studies, three open-label interventional studies and one case note review analysis. Intramuscular administration of AAV1-LPLS447X was generally well tolerated and was associated with reduction in overall pancreatitis incidence and signs of clinical improvement up to 2 years after administration. Results of interventional studies suggest that markers of postprandial metabolism could be more accurate than fasting plasma triglyceride concentration to monitor the effect of AAV1-LPLS447X . SUMMARY: The overall benefit-risk ratio of AAV1-LPLS447X gene therapy appears positive to date, particularly for the patients presenting the highest risk of complications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical trials, intramuscular injection of alipogene tiparvovec was associated with reduction in the incidence of pancreatitis and was well tolerated”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [172]
In the citing paper
“Unfortunately, TG drifted back to baseline levels within 6 months, although a few exceptional cases experienced sustained benefits.84–87”
From Clinical review on triglycerides (2020) · cites this paper as [87]
Citations
Cites
T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995) · Science · doi:10.1126/science.270.5235.475 · Cited by 1,550
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
Goldberg, I. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37569-6 · Cited by 1,010
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Self-citationState-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia
Grossman, M., Raper, S. E., Kozarsky, K., Stein, E. A., Engelhardt, J. F., Muller, D., Lupien, P. J., & Wilson, J. M. (1994) · Nature Genetics · doi:10.1038/ng0494-335 · Cited by 559
Gene therapy: trials and tribulations
Somia, N., & Verma, I. M. (2000) · Nature Reviews Genetics · doi:10.1038/35038533 · Cited by 554
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia
Johansen, C. T., Wang, J., Lanktree, M. B., Cao, H., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., et al. (2010) · Nature Genetics · doi:10.1038/ng.628 · Cited by 437
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Self-citation
Research works printed but not linked: 1
- Mingozzi, 2011, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341-355., Erratum in: Nat Rev Genet, 12, 515
Cited by
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
An essential receptor for adeno-associated virus infection
Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., et al. (2016) · Nature · doi:10.1038/nature16465 · Cited by 532
Goertsen, D., Flytzanis, N. C., Goeden, N., Chuapoco, M. R., Cummins, A., Chen, Y., Fan, Y., Zhang, Q., Sharma, J., Duan, Y., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00969-4 · Cited by 420
Hypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 387
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Gene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
“This drug was designed for a treatment of the inherited metabolic disorder lipoprotein lipase (LPL) deficiency (LPLD) (29), but unfortunately the product was withdrawn from the market in 2017.”
BackgroundDevelopment and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
“Furthermore, recombinant baculovirus technology was used for the Glybera production (Gaudet et al., 2012).”
MethodGenetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260
Self-citationVarbo, A., Benn, M., & Nordestgaard, B. G. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.008 · Cited by 251
“There has also been developed gene therapy for lipoprotein lipase deficiency, which has been shown to lower triglycerides in patients with severe hypertriglyceridemia (Gaudet et al., 2012), and are now approved for clinical use in Europe; lipoprotein lipase activators are likewise being developed (Eriksson et al.”
BackgroundTriglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237
“Intramuscular administration of alipogene tiparvovec has been shown to be generally well tolerated and is associated with clinical improvement and reduced incidence and severity of acute pancreatitis.(112) Mipomersen and lomitapide are both approved by the US Food and Drug Administration for the treatment of”
BackgroundAdiamah, A., Psaltis, E., Crook, M., & Lobo, D. N. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.028 · Cited by 175
“LPLS447X is a polymorphism occurring normally, identified in 20% of Caucasians and associated with a gain of function mutation of the LPL enzyme [83].”
BackgroundLow nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study
Thomsen, M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.219881 · Cited by 171
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“Indeed, within 12 weeks of administration, plasma TG was normalized.(88,89) Unfortunately, the effect was not sustained; TG levels returned to baseline by 6 months, possibly be-”
BackgroundThermal Stability as a Determinant of AAV Serotype Identity
Bennett, A., Patel, S., Mietzsch, M., Jose, A., Lins-Austin, B., Yu, J. C., Bothner, B., McKenna, R., & Agbandje-McKenna, M. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.003 · Cited by 159
“Significantly, a rAAV1 vector for treating lipoprotein lipase deficiency is the first approved human gene therapy biologic and was certified by the European Medical Agency.(12)”
BackgroundGenome Editing Abrogates Angiogenesis in Vivo
Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., Xiao, R., Vandenberghe, L., Zhang, F., D’Amore, P. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00140-3 · Cited by 142
Alipogene Tiparvovec: A Review of Its Use in Adults with Familial Lipoprotein Lipase Deficiency
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-014-0339-9 · Cited by 144
“lipoprotein metabolism after fat intake) or by mutations in other genes encoding proteins or enzymes that directly affect LPL function [1].”
BackgroundInfluentialAdeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
Barriers to inhaled gene therapy of obstructive lung diseases: A review
Kim, N., Duncan, G. A., Hanes, J. S., & Suk, J. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.031 · Cited by 128
“The recent approval of adeno-associated virus (AAV) type 1 as a vector for gene therapy in patients with lipoprotein lipase deficiency in Europe (GlyberaTM) [80] has provided renewed optimism in virus-mediated gene therapy.”
Gene therapy enters the pharma market: The short story of a long journey
Büning, H. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202291 · Cited by 127
“…characteristics, which were independent of the effect of alipogene tiparvovec on total TG levels; (ii) persistence of transgene expression; (iii) improvement of clinical symptoms as reported by the patients and (iv) reduced incidence and/or intensity of pancreatitis (Gaudet et al, 2012a,b).”
BackgroundMethodInfluentialImmune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury
Burnside, E. R., De Winter, F., Didangelos, A., James, N. D., Andreica, E.-C., Layard-Horsfall, H., Muir, E. M., Verhaagen, J., & Bradbury, E. J. (2018) · Brain · doi:10.1093/brain/awy158 · Cited by 111
“AAV-based gene therapy has been approved for clinical use in the treatment of genetic lipoprotein lipase deficiency (Gaudet et al., 2012) and in the CNS, AAVs are the most commonly used vector in clinical trials targeting tumours and neuronal disorders (Choudhury et al.”
MethodMeyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0006-5 · Cited by 110
“LPL gene replacement therapy has recently been approved in Europe, although its use is currently restricted to the most severely affected patients with FCS due to an LPL gene defect and recurrent pancreatitis [8,9].”
Self-citationHan, P., Wei, G., Cai, K., Xiang, X., Deng, W. P., Li, Y. B., Kuang, S., Dong, Z., Zheng, T., Luo, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14768 · Cited by 104
Gaudet, D., Stroes, E. S., Méthot, J., Brisson, D., Tremblay, K., Bernelot Moens, S. J., Iotti, G., Rastelletti, I., Ardigo, D., Corzo, D., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.158 · Cited by 100
“41 The alternative, a clinical study with an untreated control arm, would require a sample size of > 300 patients to confirm the reduction in pancreatitis rate of approximately 50% observed in this report.”
Self-citationThe Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 115
“The trials demonstrated transiently reduced fasting plasma triglyceride levels compared to baseline after 12 weeks of administration, and reduction in pancreatitis incidences [190].”
BackgroundAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 97
State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications.
Wang, D., & Gao, G. (2014) · PubMed · Cited by 127
Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J. H., Konstantinova, P. S., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 78
“Muscle represents an important tissue target for AAV vector-mediated gene transfer in muscular [14], metabolic [1] or blood-related genetic disorders [1,15,16] such as haemophilia B in which a liver-directed approach might be not possible as a result of a high prevalence of hepatitis in the patient population [17–20].”
BackgroundMethodNakajima, K., Nagamine, T., Fujita, M., Ai, M., Tanaka, A., & Schaefer, E. J. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800263-6.00003-3 · Cited by 89
Sustained Normalization of Neurological Disease after Intracranial Gene Therapy in a Feline Model
McCurdy, V. J., Johnson, A. K., Gray‐Edwards, H. L., Randle, A. N., Brunson, B. L., Morrison, N. E., Salibi, N., Johnson, J. A., Hwang, M., Beyers, R. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007733 · Cited by 70
“One cat that was symptomatic at the time of surgery (8-1626) has moderately progressive disease at 29.”
InfluentialAdeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy
Zwi‐Dantsis, L., Mohamed, S., Massaro, G., & Moeendarbary, E. (2025) · Viruses · doi:10.3390/v17020239 · Cited by 76
“The lesson learnt from the cystic fibrosis trials led the way to the approval in Europe of the first AAV gene therapy product, Glybera, for patients with lipoprotein lipase deficiency [101–103].”
Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
Geldenhuys, W. J., Lin, L., Darvesh, A. S., & Sadana, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.007 · Cited by 64
“A gene therapy designed to introduce extra copies of the functional potent enzyme in the muscles of the lower limbs of patients was introduced in Europe in 2014 [116,117].”
Furuta-Hanawa, B., Yamaguchi, T., & Uchida, E. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.031 · Cited by 60
Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines
Kotin, R. M., & Snyder, R. O. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.042 · Cited by 59
Kastelein, J. J. P., Ross, C. J., & Hayden, M. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.063 · Cited by 61
“Overall, the treatment was well tolerated, without emerging safety concerns for over 2 years after treatment (Gaudet et al. , 2012b).”
InfluentialSelf-citationHighly Efficient Ultracentrifugation-free Chromatographic Purification of Recombinant AAV Serotype 9
Tomono, T., Hirai, Y., Okada, H., Miyagawa, Y., Adachi, K., Sakamoto, S., Kawano, Y., Chono, H., Mineno, J., Ishii, A., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.015 · Cited by 55
Yuen, K., Wang, Z.-M., Wong, N.-H. M., Zhang, Z., Cheng, T.-F., Lui, W., Chan, C., & Jin, D. (2017) · Virus Research · doi:10.1016/j.virusres.2017.04.019 · Cited by 56
“also been approved for clinical use in gene therapy of familial severe hypertriglyceridemia in Europe in 2012 (Gaudet et al., 2012).”
BackgroundMethodRecent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia
Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 54
Muhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 54
The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review
Abohelwa, M., Kopel, J. J., Shurmur, S. W., Ansari, M. M., Awasthi, S., & Awasthi, S. (2023) · Journal of Vascular Diseases · doi:10.3390/jvd2010010 · Cited by 62
“Human LPL deficiency is a rare genetic disease associated with hypertriglyceridemia and pancreatitis [353].”
BackgroundPingitore, P., Lepore, S. M., Pirazzi, C., Mancina, R. M., Motta, B. M., Valenti, L. V. C., Berge, K. E., Retterstøl, K., Leren, T. P., Wiklund, O., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.02.015 · Cited by 42
“The main therapeutical approach of Type I hyperlipoproteinemia is based on diet treatment to reduce triglyceride (TG) levels.(20) TG-lowering drugs, such as niacin and fibrates, are not effective in patients with type I hyperlipoproteinemia.”
Watanabe, N., Yano, K., Tsuyuki, K., Okano, T., & Yamato, M. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.66 · Cited by 39
Bruikman, C. S., Stoekenbroek, R. M., Hovingh, G. K., & Kastelein, J. J. P. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.010 · Cited by 45
Self-citationSafety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 49
“LPL deficiency is a rare but severe condition, which impair this process, leading to extremely high triglyceride levels and recurrent pancreatitis [110,111].”
Kassner, U., Hollstein, T., Grenkowitz, T., Wühle-Demuth, M., Salewsky, B., Demuth, I., Dippel, M., & Steinhagen‐Thiessen, E. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.007 · Cited by 38
Paragh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 38
A new phenotypic classification system for dyslipidemias based on the standard lipid panel
Sampson, M. L., Ballout, R. A., Soffer, D. E., Wolska, A. T., Wilson, S. R., Meeusen, J. W., Donato, L. J., Fatica, E. M., Otvos, J. D., Brinton, E. A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01585-8 · Cited by 37
“Gene therapy for LPL deficiency was approved in Europe, but it is no longer available [55].”
BackgroundGordillo‐Marañón, M., Zwierzyna, M., Charoen, P., Drenos, F., Chopade, S., Shah, T., Engmann, J., Casas, J. P., Chaturvedi, N., Papacosta, O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25731-z · Cited by 34
“Several pharmacological attempts have been pursued to target LPL (30, 31), and gene therapy has also been applied to treat LPL deficiency by introducing extra copies of the functional enzyme in patients with hypertriglyceridemia (32).”
AAV genome modification for efficient AAV production
Asaad, W., Volos, P., Maksimov, D. O., Khavina, E. M., Deviatkin, A. A., Mityaeva, O. N., & Volchkov, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15071 · Cited by 33
Nanotheranostics Revolutionizing Gene Therapy: Emerging Applications in Gene Delivery Enhancement
Guzmán-Sastoque, P., Rodríguez, C. F., Monsalve, M. C., Castellanos, S., Manrique-Moreno, A., Reyes, L. H., & Cruz, J. C. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6020010 · Cited by 32
Hypertriglyceridemia-induced acute pancreatitis
Ewald, N. (2013) · Clinical Lipidology · doi:10.2217/clp.13.44 · Cited by 34
Wang, Z., Cheng, F., Engelhardt, J. F., Yan, Z., & Qiu, J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.09.005 · Cited by 31
Recombinant AAV9-TLK1B Administration Ameliorates Fractionated Radiation-Induced Xerostomia
Shanmugam, P. S. T., Dayton, R. D., Palaniyandi, S., Abreo, F. W., Caldito, G. C., Klein, R. L., & Sunavala‐Dossabhoy, G. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.235 · Cited by 31
“Naturally, they are in greater use in clinical trials for the treatment of a number of human diseases and genetic disorders (Gaudet et al ., 2012; Gray, 2013; Weinberg et al ., 2013).”
Blackett, P. R., Tryggestad, J. B., Krishnan, S., Li, S., Xu, W., Alaupovic, P., Quiroga, C., & Copeland, K. C. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.11.006 · Cited by 29
Tseng, Y.-S., Vliet, K. V., Rao, L., McKENNA, R. V., Byrne, B. J., Asokan, A., & Agbandje‐McKenna, M. (2016) · Journal of Virological Methods · doi:10.1016/j.jviromet.2016.07.009 · Cited by 29
Gonzaga-Jauregui, C. G., Mir, S. A. V., Penney, S., Jhangiani, S. N., Midgen, C., Finegold, M. J., Muzny, D. M., Wang, M., Bacino, C. A., Gibbs, R. A., et al. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000363 · Cited by 29
“Given recent advances in gene therapy for LPL deficiency (40,41), determining the genetic etiology of HTG helps to clarify therapeutic options and enables appropriate genetic counseling for the family.”
BackgroundMorys, S., Levačić, A. K., Urnauer, S., Kempter, S., Kern, S., Rädler, J. O., Spitzweg, C., Lächelt, U., & Wagner, E. (2017) · Polymers · doi:10.3390/polym9040142 · Cited by 32
Sun, S., Wang, J., Yao, J., Guo, H., & Dai, J. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.151509 · Cited by 27
Chen, T., Xie, S., Jin, R., & Huang, Z. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-52 · Cited by 26
“Thus, gene therapy using the S447X variant has shown therapeutic promise in the study of LPL deficiency [20].”
BackgroundAAV6 K531 serves a dual function in selective receptor and antibody ADK6 recognition
Bennett, A. D., Wong, K., Lewis, J., Tseng, Y.-S., Smith, J. K., Chipman, P., McKenna, R., Samulski, R. J., Kleinschmidt, J., & Agbandje-McKenna, M. (2018) · Virology · doi:10.1016/j.virol.2018.03.007 · Cited by 23
“Significantly, an AAV serotype 1 (AAV1) based vector packaging the lipoprotein lipase gene is the only approved gene therapy treatment marketed under the name Glybera™ (Gaudet et al., 2012).”
MethodCellular unfolded protein response against viruses used in gene therapy
Sen, D., Balakrishnan, B., & Jayandharan, G. R. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00250 · Cited by 27
“Despite significant success seen in the treatment of diseases such as lipoprotein lipase deficiency (Gaudet et al., 2012), haemophilia B (Manno et al., 2006; Nathwani et al., 2011), Leber’s Congenital Amaurosis (Simonelli et al., 2010) or severe combined immunodeficiency (SCID) (Cavazzana-Calvo et…”
BackgroundPCSK9 and resistin at the crossroads of the atherogenic dyslipidemia
Rashid, S., & Kastelein, J. J. P. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.839204 · Cited by 28
Self-citationStefanutti, C., & Julius, U. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.017 · Cited by 24
Steinhagen‐Thiessen, E., Stroes, E. S. G., Soran, H., Johnson, C., Moulin, P., Iotti, G., Zibellini, M., Ossenkoppele, B., Dippel, M., & Averna, M. R. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.023 · Cited by 25
Goertsen, D., Goeden, N., Flytzanis, N. C., & Gradinaru, V. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.010 · Cited by 26
“The first use of AAV for gene therapy was approved in 2012 to treat lipoprotein lipase deficiency.(4) Since then, clinical trials using AAVs have overwhelmingly focused on the central nervous system (CNS), eye, liver, and muscle,(5,6) with other organs like lung drastically underrepresented.”
Korpela, H., Lampela, J., Airaksinen, J., Järveläinen, N., Siimes, S., Valli, K., Nieminen, T., Turunen, M., Grönman, M., Saraste, A., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00322-9 · Cited by 22
“AAV2 based gene therapy has been studied in patients suffering from several diseases, such as lipoprotein lipase de fi ciency, neurological diseases, retinal diseases, and hemophilia [3 – 5].”
BackgroundNew trends in articular cartilage repair
Cucchiarini, M., Henrionnet, C., Mainard, D., Pinzano, A., & Madry, H. (2015) · Journal of Experimental Orthopaedics · doi:10.1186/s40634-015-0026-0 · Cited by 22
“…to express the lipoprotein lipase in the muscles of patients with lipoprotein lipase deficiency) (Carpentier et al. 2012; Gaudet et al. 2012a; Gaudet et al. 2012b; Rip et al. 2005; Ross et al. 2004), the first commercially-approved gene therapy product in the West by the European Medicines…”
BackgroundBara-Ledesma, N., Viteri-Noël, A., Rodriguez, M. L., Stamatakis, K., Fabregate, M., Vazquez-Santos, A., & del Olmo, V. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020578 · Cited by 23
Gene-based therapies in lipidology: current status and future challenges
Gaudet, D., & Brisson, D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000240 · Cited by 20
Self-citationTriglyceride-Rich Lipoproteins
Kockx, M., & Kritharides, L. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.008 · Cited by 22
Neelamekam, S., Kwok, S., Malone, R., Wierzbicki, A. S., & Soran, H. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0706-1 · Cited by 20
“This can increase the risk of exocrine and endocrine insufficiency resulting from the destruction of pancreatic parenchyma, leading to diabetes [6, 13].”
BackgroundRoundtable on etiology of familial chylomicronemia syndrome
Brown, W. V., Gaudet, D., Goldberg, I., & Hegele, R. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.12.015 · Cited by 18
Self-citationEnzyme Therapy: Current Perspectives.
Umamaheswari, T., Hemalatha, T., Sankaranarayanan, P., & Puvanakrishnan, R. (2016) · PubMed · Cited by 18
Novel therapies for severe dyslipidemia originating from human genetics
Gaudet, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000281 · Cited by 18
Self-citationAn overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Self-citationRegulatory Oversight of Cell and Gene Therapy Products in Canada
Ridgway, A. A. G., Agbanyo, F. R., Wang, J., & Rosu‐Myles, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-18618-4_3 · Cited by 17
Mehta, N., Gilbert, R., Chahal, P. S., Moreno, M., Nassoury, N., Coulombe, N., Lytvyn, V., Mercier, M., Fatehi, D., Lin, W., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.075 · Cited by 18
Management of severe hypertriglyceridemia due to lipoprotein lipase deficiency in children
Poon, S. W.-Y., Leung, K. K. Y., & Tung, J. Y. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0052 · Cited by 16
Wang, Y., Li, S., Tian, Z., Sun, J., Liang, S., Zhang, B., Bai, L., Zhang, Y., Zhou, X., Xiao, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz659 · Cited by 15
Lipoprotein lipase gene polymorphism rs1059611 functionally influences serum lipid concentrations
Mo, X., Liu, X., Wang, L., Li, H., Lu, X., Huang, J., Chen, J., Cao, J., Li, J., Chen, S., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.05.005 · Cited by 15
Afkhami, N., Aghasizadeh, M., Hafezi, S. G., Zare‐Feyzabadi, R., Soflaei, S. S., Rashidmayvan, M., Rastegarmoghadam-Ebrahimian, A., Khanizadeh, K., Safari, N., Ferns, G. A., et al. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2105 · Cited by 15
“Lipoprotein lipase deficiency is an infrequent inherited disease define by chylomicronaemia and severe hypertriglyceridemia, recurrent acute pancreatitis and increased risk of atherosclerosis or other complications (Gaudet et al., 2012; Nordestgaard et al., 1997).”
BackgroundWagner, A., Röhrs, V., Kedzierski, R., Fechner, H., & Kurreck, J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.095 · Cited by 15
“Recently, the first AAV vector-based gene therapy was approved by the European Commission for the treatment of lipoprotein lipase deficiency (Carpentier et al. , 2012; Gaudet et al. , 2012, 2013).”
Novel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
“Gene therapy targeting lipoprotein lipase ( LPL ) gene using an adeno-associated viral vector (alipogene tiparvovec, Gly-bera) initially showed promise by reducing TG levels by approximately 40% [15–17].”
Tremblay, K., Dubois-Bouchard, C., Brisson, D., & Gaudet, D. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00090 · Cited by 13
Self-citationIitake, C., Masuda, D., Koseki, M., & Yamashita, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01172-8 · Cited by 14
Severe Hypertriglyceridemia due to a novel p.Q240H mutation in the Lipoprotein Lipase gene
Soto, A. G., McIntyre, A. D., Agrawal, S., Bialo, S. R., Hegele, R. A., & Boney, C. M. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0107-1 · Cited by 11
“Therapy involving intramuscular introduction of a gain-of-function variant of the LPL gene is approved in Europe, although is costly and has only a transient effect [5].”
BackgroundLipoprotein Lipase: A General Review
Andrade, M. C. (2018) · Insights in Enzyme Research · doi:10.21767/2573-4466.100013 · Cited by 11
“LPL deficiency is a rare inherited disease that is characterized by severe hypertriglyceridemia, chylomicronemia, and the risk of recurrent pancreatitis, among other potential complications [8].”
BackgroundKassner, U., Salewsky, B., Wühle-Demuth, M., Szijártó, I. A., Grenkowitz, T., Binner, P., März, W., Steinhagen‐Thiessen, E., & Demuth, I. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.295 · Cited by 12
Schwere Hypertriglyzeridämie: Diagnostik und neue Therapieprinzipien
Kassner, U., Dippel, M., & Steinhagen‐Thiessen, E. (2017) · Der Internist · doi:10.1007/s00108-017-0234-z · Cited by 10
“Die häufigsten berichteten Nebenwirkungen waren vorübergehende Reaktionen an den Einstichstellen [30].”
Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects
Singh, K., Bhushan, B., Kumar, S., Singh, S., Macadangdang, R. R., Pandey, E., Varma, A. K., & Kumar, S. (2024) · Current Gene Therapy · doi:10.2174/0115665232279528240115075352 · Cited by 11
Mehta, N., Gilbert, R., Chahal, P. S., Moreno, M., Nassoury, N., Coulombe, N., Gingras, R., Mullick, A., Drouin, S., Sasseville, M., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00524-x · Cited by 10
Supramolecular Gene Transfection Agents
Pitard, B., & Habrant, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12563-6 · Cited by 9
Lipoprotein lipase isoelectric point isoforms in humans
Badia-Villanueva, M., Carulla, P., Carrascal, M., Abián, J., Llobera, M., Casanovas, A., & López-Tejero, M. D. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.028 · Cited by 8
“proteins that interact with LPL, such as the activating cofactor apolipoprotein C-II or GPIHBP1 [14].”
BackgroundKoch, N. V., Lifshitz, G. I., & Voronina, E. N. (2014) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2014-10-53-057 · Cited by 8
Course of Pregnancies and Occurrence of Acute Pancreatitis in Women With Chylomicronemia
Larouche, M., Bergeron, J., Brisson, D., Laflamme, N., Audet-Verreault, N., Sharon, C., Charrière, S., Rama, M., Collin‐Chavagnac, D., Moulin, P., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf409 · Cited by 9
Self-citationLipid Hydrolase Enzymes: Pragmatic Prolongevity Targets for Improved Human Healthspan?
Johnson, A. A. (2019) · Rejuvenation Research · doi:10.1089/rej.2019.2211 · Cited by 7
Establishment of a Recombinant AAV2/HBoV1 Vector Production System in Insect Cells
Deng, X., Zou, W., Yan, Z., & Qiu, J. (2020) · Genes · doi:10.3390/genes11040439 · Cited by 7
Wasserman, S. R., Muron, S., Lee, H. R., Routh, M. L., Hepperla, A. J., Scoville, D. M., Huber, A. K., Umana, J. M., Pereira, N. E., Foley, C. A., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf345 · Cited by 6
“The CMV promoter was used in the first FDA-approved gene therapy Alipogene Tiparvovec (Gly-bera) for lipoprotein lipase deficiency (LPL), while CBA is currently used in a number of FDA-approved therapies including Onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy (SMA) [ 77 , 78 ].”
Metadata
- Authors
- Gaudet, D., Méthot, J., & Kastelein, J.
- Affiliations
- Hôpital de Chicoutimi (CA)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Gaudet, Daniel
- Venue
- Current Opinion in Lipidology
- Published
- 2012-08
- Volume
- 23
- Issue
- 4
- Pages
- 310-320
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2019818397
- Cited by
- 178
- References
- 40
- Citations by year
- 2026: 2 · 2025: 14 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 32 · 2020: 5 · 2019: 12 · 2018: 11 · 2017: 14 · 2016: 18 · 2015: 19 · 2014: 15 · 2013: 14 · 2012: 1
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (CTP82941)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- lipoprotein lipase deficiency, gene therapy, hypertriglyceridemia, pancreatitis, intramuscular gene delivery, clinical trial results
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Lipoprotein Lipase, Safety, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.